$0.815
-0.0148[-1.78%]
At close: May 6
$0.815
0[0.00%]
PreMarket: 7:41PM EDT
Achilles Therapeutics
(NASDAQ:ACHL)Latest News for Achilles Therapeutics Stock (NASDAQ:ACHL)
Achilles Therapeutics Stock (NASDAQ: ACHL)
Categories: All
Friday, April 05, 2024
Thursday, April 04, 2024
- Dow Dips Over 200 Points; RPM International Shares Fall After Q3 ResultsAvi Kapoor - Apr 4, 2024, 2:39PM
- Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionAvi Kapoor - Apr 4, 2024, 1:21PM
- 12 Health Care Stocks Moving In Thursday's Intraday SessionBenzinga Insights - Apr 4, 2024, 12:31PM
- Nasdaq Surges 1%; ConAgra Brands Posts Upbeat EarningsAvi Kapoor - Apr 4, 2024, 11:58AM
- 12 Health Care Stocks Moving In Thursday's Pre-Market SessionBenzinga Insights - Apr 4, 2024, 8:09AM
- Achilles Therapeutics shares are trading lower after the company reported Q4 financial results. The company announced interim Phase I/IIa data on the use of clonal neoantigen reactive T cells from the CHIRON study in advanced unresectable or metastatic non-small cell lung cancer and the THETIS study in recurrent or metastatic malignant melanoma.Benzinga Newsdesk - Apr 4, 2024, 8:09AM
- Achilles Therapeutics Q4 EPS $(0.46) May Not Be Comparable To $(0.14) Estimate, Cash Position Of $131.5M Supports Operations Through 2025Benzinga Newsdesk - Apr 4, 2024, 6:46AM
- Achilles Therapeutics Provides Interim Phase 1/2a Update on Clonal Neoantigen Reactive T Cells In Advanced NSCLC And Melanoma Including First Patients Dosed with Enhanced Host ConditioningBenzinga Newsdesk - Apr 4, 2024, 6:32AM
Monday, December 18, 2023
Thursday, December 14, 2023
Monday, November 13, 2023
Friday, September 22, 2023
Thursday, September 07, 2023
Monday, August 07, 2023
Friday, August 04, 2023
Thursday, May 11, 2023
Wednesday, May 10, 2023
Tuesday, April 25, 2023
- Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementMichael Horton - Apr 25, 2023, 6:05PM
- Achilles Therapeutics Announces Grant Of U.S. Patent Covering Treatment Of Patients With Immunotherapy Targeting Neoantigens Based On Tumor HLA StatusBenzinga Newsdesk - Apr 25, 2023, 7:09AM
Friday, January 13, 2023
Friday, January 06, 2023
Thursday, December 15, 2022
Thursday, December 08, 2022
Wednesday, December 07, 2022
- Chardan Capital Maintains Buy on Achilles Therapeutics, Lowers Price Target to $17Benzinga Newsdesk - Dec 7, 2022, 11:50AM
- Stocks That Hit 52-Week Lows On WednesdayBenzinga Insights - Dec 7, 2022, 11:38AM
- Piper Sandler Maintains Overweight on Achilles Therapeutics, Lowers Price Target to $8Benzinga Newsdesk - Dec 7, 2022, 6:08AM
Tuesday, December 06, 2022
Friday, December 02, 2022
Tuesday, November 22, 2022
Wednesday, November 09, 2022
Tuesday, November 08, 2022
Tuesday, August 09, 2022
Monday, August 08, 2022
Monday, August 01, 2022
Tuesday, July 19, 2022
Monday, July 18, 2022
Monday, June 27, 2022
Monday, May 23, 2022
Tuesday, May 10, 2022
Monday, May 09, 2022
- Achilles Therapeutics Doses First Patient with Higher-dose cNeT in CHIRON Phase 1/2a Trial for Advanced NSCLCRagothaman Srinivasan - May 9, 2022, 10:31AM
- Achilles Therapeutics Doses First Patient With Higher-Dose cNeT In Phase I/IIa CHIRON Trial In Advanced NSCLC And Initiates Enrollment In Cohort B Of The THETIS Trial (cNeT + PD-1 checkpoint inhibitor) In Metastatic Malignant MelanomaBill Haddad - May 9, 2022, 7:19AM